Key result
FFR-guided complete revascularization significantly reduced major adverse cardiovascular events compared to IRA-only revascularization in STEMI patients (OR 0.55; 95% CI 0.42-0.72; P<0.001).
Why the study?
It was not clear whether outcomes are improved by utilizing fractional flow reserve-guided percutaneous coronary intervention of noninfarct related arteries along with primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction and multivessel disease.
Does FFR-guided complete revascularization reduce major adverse cardiovascular events compared to IRA-only revascularization in patients with STEMI and multivessel coronary artery disease?
Meta-Analysis (n=1,633)
Does FFR-guided complete revascularization reduce major adverse cardiovascular events compared to IRA-only revascularization in patients with STEMI and multivessel coronary artery disease?
Odds Ratio: 0.55 (95% CI 0.42–0.72)
p-value: p=<0.001
FFR-guided complete revascularization in STEMI patients with multivessel disease significantly reduces MACE, driven primarily by a reduction in repeat revascularization, compared to IRA-only PCI.
Supports FFR-guided non-IRA PCI in multivessel STEMI; reinforces pooled RCT evidence for clinical benefit.
In Brief Background Multivessel coronary artery disease is found in 30–50% of patients with ST-elevation myocardial infarction (MI) and is associated with adverse outcomes. It is not yet clear if outcomes are improved by utilizing fractional flow reserve (FFR) guided percutaneous coronary intervention (PCI) of noninfarct related artery (non-IRA) along with primary PCI. Methods and results To evaluate this, we performed a metanalysis of published randomized controlled trials by performing systematic search of PubMed, Medline, Google Scholar and Cochrane Central. Three studies met the inclusion criteria, with total of 1633 patients; 689 underwent FFR-guided complete revascularization and 944 underwent IRA only revascularization. FFR-guided PCI of non-IRA along with primary PCI led to significant reduction of major adverse cardiovascular events (composite of death, MI and repeat revascularization) compared to PCI of IRA only [odds ratio (OR) = 0.55; 95% confidence interval (CI) = 0.42–0.72; P < 0.001]. This difference was primarily due to significant reduction in repeat revascularization (OR = 0.37; 95% CI = 0.26–0.53; P < 0.001). The rates of all-cause mortality (OR = 1.24; 95% CI = 0.65–2.35; P = 0.51) and MI (OR = 0.79; 95% CI = 0.46–1.36; P = 0.48) were similar in two groups. Conclusion This meta-analysis demonstrated that FFR-guided PCI of non-IRA along with primary PCI was associated with lower rate of major adverse cardiovascular events compared with PCI of IRA-only in patients with ST-elevation MI and multivessel disease. The difference was driven by lower rate of repeat revascularization in FFR-guided PCI of non-IRA group. This metanalysis was performed to evaluate if outcomes are improved by utilizing fractional flow reserve (FFR) guided percutaneous coronary intervention (PCI) of non-infarct related artery (non-IRA) along with primary PCI. Three studies met the inclusion criteria, with total of 1633 patients; 689 underwent FFR-guided complete revascularization and 944 underwent IRA only revascularization. FFR-guided PCI of non-IRA along with primary PCI led to significant reduction of major adverse cardiovascular events (MACE; composite of death, myocardial infarction and repeat revascularization) compared to PCI of IRA only [OR=0.55 (95% CI=0.42-0.72), p<0.001] This difference was primarily due to significant reduction in repeat revascularization [OR=0.37 ([95% CI=0.26-0.53), p<0.001].
No takes yet. Share an insight, caveat, or question.
Neupane et al. (2019) conducted a meta-analysis in ST-elevation myocardial infarction and multivessel coronary artery disease (n=1,633). Fractional flow reserve (FFR) guided percutaneous coronary intervention (PCI) of non-infarct related artery (non-IRA) along with primary PCI vs. Infarct related artery (IRA) only revascularization was evaluated on Major adverse cardiovascular events (composite of death, MI and repeat revascularization) (OR 0.55, 95% CI 0.42-0.72, p=<0.001). FFR-guided complete revascularization significantly reduced major adverse cardiovascular events compared to IRA-only revascularization in STEMI patients (OR 0.55; 95% CI 0.42-0.72; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: